Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

428 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The association between early ventricular arrhythmias, renin-angiotensin-aldosterone system antagonism, and mortality in patients with ST-segment-elevation myocardial infarction: Insights from Global Use of Strategies to Open coronary arteries (GUSTO) V.
Askari AT, Shishehbor MH, Kaminski MA, Riley MJ, Hsu A, Lincoff AM; GUSTO-V Investigators. Askari AT, et al. Among authors: lincoff am. Am Heart J. 2009 Aug;158(2):238-43. doi: 10.1016/j.ahj.2009.05.023. Am Heart J. 2009. PMID: 19619700 Clinical Trial.
Significance of a coronary artery with thrombolysis in myocardial infarction grade 2 flow "patency" (outcome in the thrombolysis and angioplasty in myocardial infarction trials). Thrombolysis and Angioplasty in Myocardial Infarction Study Group.
Lincoff AM, Topol EJ, Califf RM, Sigmon KN, Lee KL, Ohman EM, Rosenschein U, Ellis SG. Lincoff AM, et al. Am J Cardiol. 1995 May 1;75(14):871-6. doi: 10.1016/s0002-9149(99)80678-x. Am J Cardiol. 1995. PMID: 7732992 Clinical Trial.
Standard versus low-dose weight-adjusted heparin in patients treated with the platelet glycoprotein IIb/IIIa receptor antibody fragment abciximab (c7E3 Fab) during percutaneous coronary revascularization. PROLOG Investigators.
Lincoff AM, Tcheng JE, Califf RM, Bass T, Popma JJ, Teirstein PS, Kleiman NS, Hattel LJ, Anderson HV, Ferguson JJ, Cabot CF, Anderson KM, Berdan LG, Musco MH, Weisman HF, Topol EJ. Lincoff AM, et al. Am J Cardiol. 1997 Feb 1;79(3):286-91. doi: 10.1016/s0002-9149(96)00749-7. Am J Cardiol. 1997. PMID: 9036746 Clinical Trial.
Influence of local delivery of the protein tyrosine kinase receptor inhibitor tyrphostin-47 on smooth-muscle cell proliferation in a rat carotid balloon-injury model.
Gottsauner-Wolf M, Jang Y, Lincoff AM, Cohen JL, Labhasetwar V, Poptic EJ, Forudi F, Guzman LA, DiCorleto PE, Levy RJ, Topol EJ, Ellis SG. Gottsauner-Wolf M, et al. Among authors: lincoff am. Am Heart J. 1997 Mar;133(3):329-34. doi: 10.1016/s0002-8703(97)70228-x. Am Heart J. 1997. PMID: 9060802
Evidence for prevention of death and myocardial infarction with platelet membrane glycoprotein IIb/IIIa receptor blockade by abciximab (c7E3 Fab) among patients with unstable angina undergoing percutaneous coronary revascularization. EPIC Investigators. Evaluation of 7E3 in Preventing Ischemic Complications.
Lincoff AM, Califf RM, Anderson KM, Weisman HF, Aguirre FV, Kleiman NS, Harrington RA, Topol EJ. Lincoff AM, et al. J Am Coll Cardiol. 1997 Jul;30(1):149-56. doi: 10.1016/s0735-1097(97)00110-1. J Am Coll Cardiol. 1997. PMID: 9207636 Free article. Clinical Trial.
Platelet glycoprotein IIb/IIIa receptor blockade with abciximab reduces ischemic complications in patients undergoing directional coronary atherectomy. EPILOG Investigators. Evaluation of PTCA to Improve Long-term Outcome by c7E3 GP IIb/IIIa Receptor Blockade.
Ghaffari S, Kereiakes DJ, Lincoff AM, Kelly TA, Timmis GC, Kleiman NS, Ferguson JJ, Miller DP, Califf RA, Topol EJ. Ghaffari S, et al. Among authors: lincoff am. Am J Cardiol. 1998 Jul 1;82(1):7-12. doi: 10.1016/s0002-9149(98)00238-0. Am J Cardiol. 1998. PMID: 9671000 Clinical Trial.
428 results